太阳集团tyc5997_平台(china)官方网站

末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法)

Multiplex Assay Kit for Terminal Complement Complex C5b-9 (C5b-9) ,etc. by FLIA (Flow Luminescence Immunoassay)

MAC; Membrane Attack Complex

(注:单次混测多因子不超过8个指标 )

  • 末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法) 产品包装(模拟)
  • 末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法) 产品包装(模拟)
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

特异性

本试剂盒用于检测末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。

回收率

分别于定值血清及血浆样本中加入一定量的末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。

样本 回收率范围(%) 平均回收率(%)
serum(n=5) 81-91 87
EDTA plasma(n=5) 84-101 95
heparin plasma(n=5) 84-98 88
sodium citrate plasma(n=5) 84-99 92

精密度

精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%

线性

在定值血清及血浆样本内加入适量的末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法)含量的测定值与理论值的比率。

样本 1:2 1:4 1:8 1:16
serum(n=5) 83-97% 93-101% 92-105% 91-99%
EDTA plasma(n=5) 78-95% 93-101% 78-88% 99-105%
heparin plasma(n=5) 98-105% 83-93% 82-101% 97-104%
sodium citrate plasma(n=5) 93-101% 93-101% 79-98% 88-98%

稳定性

经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。

实验流程

1. 实验前标准品、试剂及样本准备;
2. 加样(标准品、样本、磁珠)标准品或样本100μL及磁珠10μL,
    37°C酶标板振荡器孵育90分钟;
3. 磁吸甩干,加检测溶液A100μL,37°C酶标板振荡器孵育60分钟;
4. 磁吸洗板3次;
5. 加检测溶液B100μL,37°C振动孵育30分钟;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋涡震荡2分钟后读数。

实验原理

将末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法)抗体包被于磁珠,制成固相载体,向微孔中分别加入标准品或标本以及磁珠,其中的末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法)与连接于固相载体上的抗体结合,然后加入生物素化的末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法)抗体,将未结合的生物素化抗体洗净后,加入PE标记的亲和素,再次彻底洗涤后即可上机读数。MFI值和样品中的末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法)呈正相关。

赠品

相关产品

编号 适用物种:Mus musculus (Mouse,小鼠) 应用(仅供研究使用,不用于临床诊断!)
SEC350Mu 末端补体复合体C5b-9(C5b-9)检测试剂盒(酶联免疫吸附试验法) Enzyme-linked immunosorbent assay for Antigen Detection.
LMC350Mu 末端补体复合体C5b-9(C5b-9)等多因子检测试剂盒(流式荧光发光法) FLIA Kit for Antigen Detection.

参考文献

杂志 参考文献
Journal of Biomedical Materials Research Part A Effect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles [Wiley: source]
The Journal of Clinical Investigation Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis [PubMed: PMC3195471]
Colloids and Surfaces B: Biointerfaces Glucosylated polymeric nanoparticles: A sweetened approach against blood compatibility paradox [ScienceDirect: S0927776513001720]
Perfusion The effect of normovolemic modified ultrafiltration on inflammatory mediators, endotoxins, terminal complement complexes and clinical outcome in high-risk cardiac surgery patients [Pubmed: 23429100]
Nephrology Dialysis Transplantation The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin associated hemolytic uremic syndrome model mice [Pubmed:25694534]
journal of neuroinflammation Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial [PubMed: 26272468]
J Thromb Haemost Thrombin‐activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis [PubMed: 26340319]
Digital Repository Dosagem de frações ativadas do sistema complemento em empiema induzido em ratos [10183]
J Neuroinflammation.  Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis [PMC5234106]
Cancer Letters Complement C5a/C5aR pathway potentiates the pathogenesis Q5 of gastric cancer by down-regulating p21 expression [pubmed:29031586]
Effects of immunoadsorption combined with membrane filtration on complement markers–Results of a randomized, controlled, crossover study []
Journal of Neuroinflammation Complement factor H contributes to mortality in humans and mice with bacterial meningitis [Pubmed: 31883521]
FASEB J C‐reactive protein inhibits C3a/C3aR‐dependent podocyte autophagy in favor of diabetic kidney disease [Pubmed:35503088]
留言咨询
Baidu
sogou